Literature DB >> 29973350

Overdiagnosis and overtreatment in rheumatology: a little caution is in order.

Robert B M Landewé1,2.   

Abstract

Overdiagnosis is a term coined by experts in cancer screening to point to indolent cancers detected by screening that would have never led to manifest health problems. Overdiagnosis leads to unnecessary medical care (overtreatment), anxiety and cost. In rheumatology overdiagnosis and overtreatment are hardly discussed but likely present. This viewpoint examines how our prevailing views on the management of inflammatory rheumatic diseases may relate to overdiagnosis and overtreatment. Six paradigms of modern rheumatology will be discussed: early diagnosis, intensive treatment, remission, prognosis and risk stratification, evidence-based rheumatology, and precision medicine. It is concluded that, in spite of the enormous progress that they have brought, all paradigms bear the intrinsic dangers of overdiagnosis and overtreatment. So a little caution is in order. © Author(s) (or their employer(s)) 2018. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  early rheumatoid arthritis; patient perspective; psoriatic arthritis; spondyloarthritis; treatment

Mesh:

Year:  2018        PMID: 29973350     DOI: 10.1136/annrheumdis-2018-213700

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  12 in total

Review 1.  Value-Based Healthcare in Rheumatology: Axial Spondyloarthritis and Beyond.

Authors:  David F L Liew; Jonathan Dau; Philip C Robinson
Journal:  Curr Rheumatol Rep       Date:  2021-04-28       Impact factor: 4.592

Review 2.  Early-stage symptomatic osteoarthritis of the knee - time for action.

Authors:  Armaghan Mahmoudian; L Stefan Lohmander; Ali Mobasheri; Martin Englund; Frank P Luyten
Journal:  Nat Rev Rheumatol       Date:  2021-08-31       Impact factor: 20.543

3.  Pragmatic randomised controlled trial of very early etanercept and MTX versus MTX with delayed etanercept in RA: the VEDERA trial.

Authors:  Paul Emery; Sarah Horton; Raluca Bianca Dumitru; Kamran Naraghi; Désirée van der Heijde; Richard J Wakefield; Elizabeth M A Hensor; Maya H Buch
Journal:  Ann Rheum Dis       Date:  2020-01-29       Impact factor: 19.103

Review 4.  Measuring ACPA in the general population or primary care: is it useful?

Authors:  Axel Finckh; Delphine Courvoisier; Celine Lamacchia
Journal:  RMD Open       Date:  2020-02

5.  Accuracy, patient-perceived usability, and acceptance of two symptom checkers (Ada and Rheport) in rheumatology: interim results from a randomized controlled crossover trial.

Authors:  Axel J Hueber; Martin Welcker; Johannes Knitza; Jacob Mohn; Christina Bergmann; Eleni Kampylafka; Melanie Hagen; Daniela Bohr; Harriet Morf; Elizabeth Araujo; Matthias Englbrecht; David Simon; Arnd Kleyer; Timo Meinderink; Wolfgang Vorbrüggen; Cay Benedikt von der Decken; Stefan Kleinert; Andreas Ramming; Jörg H W Distler; Nicolas Vuillerme; Achim Fricker; Peter Bartz-Bazzanella; Georg Schett
Journal:  Arthritis Res Ther       Date:  2021-04-13       Impact factor: 5.156

6.  EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis.

Authors:  György Nagy; Nadia M T Roodenrijs; Désirée van der Heijde; Jacob M van Laar; Paco M J Welsing; Melinda Kedves; Attila Hamar; Marlies C van der Goes; Alison Kent; Margot Bakkers; Polina Pchelnikova; Etienne Blaas; Ladislav Senolt; Zoltan Szekanecz; Ernest H Choy; Maxime Dougados; Johannes Wg Jacobs; Rinie Geenen; Johannes Wj Bijlsma; Angela Zink; Daniel Aletaha; Leonard Schoneveld; Piet van Riel; Sophie Dumas; Yeliz Prior; Elena Nikiphorou; Gianfranco Ferraccioli; Georg Schett; Kimme L Hyrich; Ulf Mueller-Ladner; Maya H Buch; Iain B McInnes
Journal:  Ann Rheum Dis       Date:  2021-08-18       Impact factor: 19.103

7.  Anti-Citrullinated Protein Antibody Titers Are Independently Modulated by Both Disease Activity and Conventional or Biologic Anti-Rheumatic Drugs.

Authors:  Miren Uriarte Ecenarro; Daniel Useros; Aranzazu Alfranca; Reyes Tejedor; Isidoro González-Alvaro; Rosario García-Vicuña
Journal:  Diagnostics (Basel)       Date:  2022-07-21

8.  One in five patients with rapidly and persistently controlled early rheumatoid arthritis report poor well-being after 1 year of treatment.

Authors:  Kristien Van der Elst; Patrick Verschueren; Diederik De Cock; An De Groef; Veerle Stouten; Sofia Pazmino; Johanna Vriezekolk; Johan Joly; Philip Moons; René Westhovens
Journal:  RMD Open       Date:  2020-04

9.  Validation of galectin-1 as potential diagnostic biomarker of early rheumatoid arthritis.

Authors:  Ana Triguero-Martínez; Hortensia de la Fuente; Nuria Montes; Ana María Ortiz; Emilia Roy-Vallejo; Santos Castañeda; Isidoro González-Alvaro; Amalia Lamana
Journal:  Sci Rep       Date:  2020-10-20       Impact factor: 4.379

10.  What do patients prefer? A multinational, longitudinal, qualitative study on patient-preferred treatment outcomes in early rheumatoid arthritis.

Authors:  Kristien Van der Elst; Elke G E Mathijssen; Ellen Landgren; Ann Bremander; An De Groef; Elisabet Lindqvist; Maria Nylander; Alma Peters; Frank Van den Hoogen; Yvonne van Eijk-Hustings; Gerard Verhoeven; Johanna E Vriezekolk; Rene Westhovens; Ingrid Larsson
Journal:  RMD Open       Date:  2020-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.